With new drug development, a significant increase in sales, and high potential with Mounjaro and Zepbound, here’s what we think of Eli Lilly’s stock ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Eli Lilly and Company's correction may be coming to an end as the actual demand for its drugs seems to be holding well. Learn more about LLY stock here.

Alphabet also remains a popular pick among hedge fund managers. According to Insider Monkey data, 202 hedge fund investors ...

We recently compiled a list of the 15 Best Large-Cap Value Stocks to Buy in 2025. In this article, we are going to take a ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so far in 2025. On Jan. 14, shares of Lilly ...

Lilly’s fourth-quarter estimates, the fourth quarter that we just finished ... I gotta tell you, however, I can’t think of a ...

Is Eli Lilly a good stock to buy on the dip? Here's a look at why it's been ... leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing growth for a drug that launched in 2022.

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December ...

On Wednesday, Bernstein analysts maintained their positive stance on Eli Lilly stock (NYSE:LLY), reiterating an Outperform ... which indicated a shortfall in the fourth quarter GLP-1 revenue compared ...

Highline Wealth Partners LLC lifted its holdings in Eli Lilly and Company by 80.0% during the fourth quarter. Highline Wealth Partners LLC now owns 45 shares of the company’s stock valued at $ ...